Merck & Co.
AWARDS
NEWS
It doesn’t happen that often, but Merck’s checkpoint inhibitor Keytruda received a rejection from the U.S. Food and Drug Administration.
The U.S. Food and Drug Administration has a busy week planned for drug review. Here’s a look at this week’s schedule.
It was a very busy week for clinical trial news. Here’s a look.
Screening using EMR data could help with early identification of Alzheimer’s disease risk
Merck’s checkpoint inhibitor Keytruda (pembrolizumab) proved itself effective in yet another cancer indication.
“We appreciate Merck’s willingness to work with us on the advancement of plasma kallikrein inhibitors for DME, and we respect their decision not to move forward,” said Andrew Crockett, KalVista’s chief executive officer.
JOBS
IN THE PRESS